OBJECTIVE: To characterize total body bone mineral content (BMC) and total body and spinal bone mineral density (BMD) in perinatally HIV-infected and uninfected children/youth across puberty. DESIGN: HIV-infected (7-24 years) were randomly selected from six strata based on Tanner stage/protease inhibitor use. HIV-uninfected were frequency-matched by Tanner group and sociodemographic background to the HIV-infected. METHODS: Dual-energy X-ray absorptiometry (DXA) measured BMC and BMD. Linear regression models tested differences in bone outcomes by HIV and the interaction of HIV by Tanner group (1-2, 3-4, 5). Models were performed separately by sex and adjusted for DXA scanner, race/ethnicity, height, age and lean body mass. RESULTS: HIV-infected (N = 236) and uninfected (N = 143) were comparable on sex and race/ethnicity. HIV-infected were slightly older (median 12.6 versus 11.9 years). In adjusted models, HIV-infected males had significantly lower total body BMC and total body and spinal BMD at Tanner 5, lower BMC at Tanner 3-4 and similar BMC and BMD at Tanner 1-2, compared to HIV-uninfected males. HIV-infected and uninfected girls did not differ significantly on any bone outcome, but there was a marginally significant interaction of HIV and Tanner group for spinal BMD. Kaletra/ritonavir was associated with lower BMC and total body BMD and nevirapine was associated with higher spinal BMD in a model with all HIV-infected. CONCLUSIONS: Perinatally HIV-infected males showed more evidence of lower bone density especially in the final stage of pubertal development than HIV-infected girls and they may be at increased risk for bone disease during adulthood.
OBJECTIVE: To characterize total body bone mineral content (BMC) and total body and spinal bone mineral density (BMD) in perinatally HIV-infected and uninfected children/youth across puberty. DESIGN:HIV-infected (7-24 years) were randomly selected from six strata based on Tanner stage/protease inhibitor use. HIV-uninfected were frequency-matched by Tanner group and sociodemographic background to the HIV-infected. METHODS: Dual-energy X-ray absorptiometry (DXA) measured BMC and BMD. Linear regression models tested differences in bone outcomes by HIV and the interaction of HIV by Tanner group (1-2, 3-4, 5). Models were performed separately by sex and adjusted for DXA scanner, race/ethnicity, height, age and lean body mass. RESULTS:HIV-infected (N = 236) and uninfected (N = 143) were comparable on sex and race/ethnicity. HIV-infected were slightly older (median 12.6 versus 11.9 years). In adjusted models, HIV-infected males had significantly lower total body BMC and total body and spinal BMD at Tanner 5, lower BMC at Tanner 3-4 and similar BMC and BMD at Tanner 1-2, compared to HIV-uninfected males. HIV-infected and uninfected girls did not differ significantly on any bone outcome, but there was a marginally significant interaction of HIV and Tanner group for spinal BMD. Kaletra/ritonavir was associated with lower BMC and total body BMD and nevirapine was associated with higher spinal BMD in a model with all HIV-infected. CONCLUSIONS: Perinatally HIV-infected males showed more evidence of lower bone density especially in the final stage of pubertal development than HIV-infectedgirls and they may be at increased risk for bone disease during adulthood.
Authors: Denise L Jacobson; Donna Spiegelman; Christopher Duggan; Geoffrey A Weinberg; Lori Bechard; Lauren Furuta; Jeanne Nicchitta; Sherwood L Gorbach; Tracie L Miller Journal: J Pediatr Gastroenterol Nutr Date: 2005-09 Impact factor: 2.839
Authors: Jon M Burnham; Justine Shults; Edisio Semeao; Bethany Foster; Babette S Zemel; Virginia A Stallings; Mary B Leonard Journal: J Bone Miner Res Date: 2004-09-20 Impact factor: 6.741
Authors: G Theintz; B Buchs; R Rizzoli; D Slosman; H Clavien; P C Sizonenko; J P Bonjour Journal: J Clin Endocrinol Metab Date: 1992-10 Impact factor: 5.958
Authors: Shirin Heidari; Lynne M Mofenson; Charlotte V Hobbs; Mark F Cotton; Richard Marlink; Elly Katabira Journal: J Acquir Immune Defic Syndr Date: 2012-02-01 Impact factor: 3.731
Authors: Julie J Kim-Chang; Lorena Wilson; Cliburn Chan; Bernard Fischer; Guglielmo Venturi; Maureen M Goodenow; Grace Aldrovandi; Thomas J Weber; John W Sleasman Journal: AIDS Res Hum Retroviruses Date: 2019-06-27 Impact factor: 2.205
Authors: Linda A DiMeglio; JiaJia Wang; George K Siberry; Tracie L Miller; Mitchell E Geffner; Rohan Hazra; William Borkowsky; Janet S Chen; Laurie Dooley; Kunjal Patel; Russell B van Dyke; Roger A Fielding; Yared Gurmu; Denise L Jacobson Journal: AIDS Date: 2013-01-14 Impact factor: 4.177